Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes Journal Article


Authors: Barakat, R. R.; Federici, M. G.; Saigo, P. E.; Robson, M. E.; Offit, K.; Boyd, J.
Article Title: Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes
Abstract: BACKGROUND. The high mortality associated with ovarian carcinoma is largely a reflection of the inability to diagnose the disease at an early stage; the identification of a histologic lesion or molecular marker associated early stages of transformation would represent an important advance in understanding the natural history of this cancer. The existence of individuals with germline mutations in the ovarian and breast carcinoma susceptibility gene BRCA1 represents a unique opportunity to search for such premalignant alterations in ovarian tissues that are at unusually high risk for tumorigenesis. In this study, the authors addressed the hypothesis that pathologically normal ovaries removed from BRCA1 heterozygotes are likely to display premalignant histologic, molecular, and/or cell biologic alterations that may provide insight into early stages of ovarian tumorigenesis. METHODS. Ovarian tissues from 18 BRCA1 heterozygotes and from 20 age-matched controls were examined in a blinded fashion for histologic evidence of surface epithelial pseudostratification, epithelial inclusion cysts, deep cortical invaginations of surface epithelium, increased stromal cell activity, and surface papillomatosis. Immunohistochemical analyses for expression of BRCA1, p53, and ERBB-2 and quantitation of cell proliferation (Ki-67 expression) and apoptosis (TUNEL assay), were also performed on all specimens. RESULTS. Although histologic alterations were observed, there was no difference in frequency between cases and controls. Analysis of BRCA1 expression revealed ubiquitous nuclear immunoreactivity in the surface epithelial cells of all ovaries. Similarly, no evidence was found of p53 overexpression in any ovarian tissue or of a difference in ERBB-2 expression between cases and controls. Finally, no differences were observed in epithelial cell proliferation or apoptosis. CONCLUSIONS. Clinically, normal ovaries from BRCA1 heterozygotes do not show evidence of premalignant alterations in histology, molecular markers, cell proliferation, or apoptosis, indicating that such changes are likely rare. (C) 2000 American Cancer Society.
Keywords: adult; clinical article; controlled study; human tissue; protein expression; aged; histopathology; ki 67 antigen; cell proliferation; ki-67 antigen; ovarian neoplasms; cell death; cell division; cancer susceptibility; cancer prevention; apoptosis; gene expression; ovariectomy; cell protein; brca1 protein; heterozygote; protein p53; morphology; ovary; early diagnosis; genes, brca1; ovary carcinoma; ovarian carcinoma; brca1; germ-line mutation; p53; hereditary; precancerous conditions; middle age; premalignant; human; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; erbb- 2
Journal Title: Cancer
Volume: 89
Issue: 2
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2000-07-15
Start Page: 383
End Page: 390
Language: English
DOI: 10.1002/1097-0142(20000715)89:2<383::aid-cncr25>3.0.co;2-t
PUBMED: 10918170
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Kenneth Offit
    791 Offit
  2. Richard R Barakat
    629 Barakat
  3. Mark E Robson
    682 Robson
  4. Jeffrey Boyd
    112 Boyd
  5. Patricia E Saigo
    91 Saigo